Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Study Number

4348925

Phase

Age Group

Adult

Principal Investigator

Purpose

This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.

Check your eligibility for this trial

Check now

Full Title

A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

ClinicalTrials.Gov ID

NCT06846606

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.